Eli Lilly’s acquisition of SiteOne Therapeutics acquisition comes ahead of Phase 2 testing of the startup’s lead drug candidate, which blocks the NaV1.8 sodium channel to treat pain. This target has clinical and regulatory validation from the recent FDA approval of Vertex Pharmaceuticals’ pain drug, Journavx.
The post Eli Lilly Commits $1B to Get Drug That Could Rival Vertex’s New Non-Opioid Pain Med appeared first on MedCity News.
